Effects of Plant Foods on Gastrointestinal and Cardiometabolic Health
PLANTIFUL
A Randomised Controlled Trial Investigating the Impact of Plant Foods on Gastrointestinal and Cardiometabolic Health
1 other identifier
interventional
248
1 country
1
Brief Summary
The aim of this randomised controlled trial is to investigate the effects of plant foods on gastrointestinal and cardiometabolic health in healthy adults aged 30-70 years old. The main question it will answer is "what is the effect of plant foods on alpha-diversity of the gut microbiota?". Researchers will compare two diets containing plant foods to see if they have different effects on gastrointestinal and cardiometabolic health. Participants will be asked to replace all their meals, snacks and drinks with those provided by the study team for four weeks (6 days/week). Participants will also be asked to attend the research facility on three occasions to:
- Provide a blood sample
- Provide a urine sample
- Provide a stool sample
- Have their body composition assessed
- Have an ultrasound of their artery (arm)
- Have their blood pressure measured
- Answer questionnaires related to dietary intake, mental health, physical activity, quality of life, diet acceptability and adherence
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Apr 2026
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2026
CompletedFirst Submitted
Initial submission to the registry
April 17, 2026
CompletedFirst Posted
Study publicly available on registry
May 14, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
November 1, 2028
May 14, 2026
October 1, 2025
2.5 years
April 17, 2026
May 7, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Alpha-diversity of the gut microbiota
The diversity of microbial taxa in faecal samples at 4 weeks assessed by calculating alpha-diversity score from 16S ribosomal RNA sequencing.
Week 4
Secondary Outcomes (18)
Absolute and change in alpha-diversity of the gut microbiota
Baseline, Week 4
Beta-diversity of the gut microbiota
Baseline, Week 4
Microbiota composition
Baseline, Week 4
Targeted faecal and plasma metabolomics
Baseline, Week 4
Targeted faecal and plasma metabolomics
Baseline, Week 4
- +13 more secondary outcomes
Other Outcomes (5)
Health-related Quality of Life
Baseline, Week 4
Mental Health
Baseline, Week 4
Diet acceptability
Baseline, Week 4
- +2 more other outcomes
Study Arms (2)
Study Diet A
ACTIVE COMPARATORMeals, snacks and drinks that contain plant foods provided by the research team for four weeks (6 days a week).
Study Diet B
ACTIVE COMPARATORMeals, snacks and drinks that contain plant foods provided by the research team for four weeks (6 days a week).
Interventions
Study meals, snacks and drinks will be provided that contain plant foods for four weeks (6 days a week). Participants will follow guidance in self-selecting foods on one day per week.
Study meals, snacks and drinks will be provided that contain plant foods for four weeks (6 days a week). Participants will follow guidance in self-selecting foods on one day per week.
Eligibility Criteria
You may qualify if:
- Adults aged 30-70 years of age
- Capacity to give informed consent in English
- Consume equal or less than the average UK plant food intake (number and quantity)
- Consume less than 30 g/d of fibre
- BMI 18.50-29.99 kg/m2
- Willing to complete the trial by adhering to the diet intervention, complete questionnaires, provide stool, urine and blood samples, record weight and other anthropometric values and record food intake throughout the study
- Willing and able to adhere to the protocol for the diet intervention for the whole duration of the trial (e.g., appropriate space in freezer to store meals, access to oven/microwave, no planned travelling)
- Willing to discontinue use of prebiotics and probiotics 4 weeks prior and during the intervention period
- Willing to consume animal products daily
- Medication use is stable in women receiving hormone replacement therapy (stable use for the past 3 months)
You may not qualify if:
- Medical history of any of the following: diabetes, major active or historic psychiatric conditions (e.g., schizophrenia), current eating disorder, alcohol abuse, active treatment for cancer in the last year, severe neurological, endocrine, renal, cardiac or pulmonary disease (or any other chronic medical condition), severe oesophagitis, gastritis or duodenitis, active diverticulitis or intestinal/colonic strictures, Coeliac disease, Crohn's disease or Ulcerative colitis, stem cell or organ transplant, gut resection surgery (excluding appendicectomy and cholecystectomy), bleeding disorder, anaphylaxis or any other major or chronic condition known to impact study outcome measures.
- A current diagnosis of IBS, as defined by the Rome IV criteria.
- Taking medications known to affect outcomes of interest, including:
- Prebiotics and probiotics 4 weeks prior to enrolment.
- Antibiotics within 4 weeks of enrolment.
- Medications known to affect blood pressure, appetite, gut motility, glucose control, or lipid levels within 4 weeks of enrolment.
- Taking any dietary supplements, apart from vitamin D or calcium supplements, 4 weeks prior to enrolment.
- Allergy or intolerance to any study food ingredients.
- Unable/dislike/unwilling to consume study foods or adhere to study protocol (e.g., not willing to drink a maximum 9 units of alcohol a week or consume animal products).
- Currently reported pregnant or lactating.
- Unwilling or unable to consume non-halal or non-kosher products.
- Estimated energy requirements of \<1,500 kcal/day or \>3,000 kcal/day.
- Unexplained or unintentional weight loss in the past six months.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- King's College Londonlead
- Biotechnology and Biological Sciences Research Councilcollaborator
- University of Southamptoncollaborator
- University of Leedscollaborator
Study Sites (1)
King's College London
London, SE1 9NH, United Kingdom
Related Links
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 17, 2026
First Posted
May 14, 2026
Study Start
April 1, 2026
Primary Completion (Estimated)
October 1, 2028
Study Completion (Estimated)
November 1, 2028
Last Updated
May 14, 2026
Record last verified: 2025-10